Replimune Group (REPL) closed at $11.99 on October 22, 2026, up 2.3% from the previous close, on volume of 1,662,812 shares (30-day average 1,987,856).
Data as of October 22, 2026.
22-Oct-2026
Replimune Sets Oct. 28 Call to Detail Fiscal Q2 2027 Results and a Corporate Update
Market Chameleon (Thu, 22-Oct 4:03 AM ET)
Globe Newswire (Thu, 22-Oct 8:00 AM ET)
Globe Newswire (Mon, 5-Oct 12:19 PM ET)
ACCESS Newswire (Fri, 2-Oct 10:30 AM ET)
Replimune Announces TUDRIQEV Now Available in the U.S. for Advanced Melanoma
Globe Newswire (Thu, 1-Oct 4:01 PM ET)
PRNewswire (Thu, 1-Oct 10:10 AM ET)
PRNewswire (Wed, 30-Sep 12:52 PM ET)
Globe Newswire (Tue, 29-Sep 5:17 PM ET)
Globe Newswire (Tue, 29-Sep 12:09 PM ET)
Globe Newswire (Tue, 29-Sep 10:13 AM ET)
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Replimune Group trades on the NASDAQ stock market under the symbol REPL.
As of October 22, 2026, REPL stock price climbed to $11.99 with 1,662,812 million shares trading.
REPL has a beta of -0.39, meaning it tends to be less sensitive to market movements. REPL has a correlation of 0.00 to the broad based SPY ETF.
REPL has a market cap of $1.13 billion. This is considered a Small Cap stock.
Last quarter Replimune Group reported $0 in Revenue and -$.72 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.04.
In the last 3 years, REPL traded as high as $17.00 and as low as $1.50.
The top ETF exchange traded funds that REPL belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
REPL has outperformed the market in the last year with a return of +48.0%, while the SPY ETF gained +14.9%. In the last 3 month period, REPL beat the market returning +9.0%, while SPY returned +2.3%. However, in the most recent 2 weeks REPL has underperformed the stock market by returning -9.2%, while SPY returned -1.7%.
REPL support price is $11.25 and resistance is $12.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REPL shares will trade within this expected range on the day.
